Pharmacokinetics of conivaptan use in patients with severe hepatic impairment
Thomas Marbury,1 Jerry Fox,2 Byron Kaelin,2 Leo Pavliv2 1Orlando Clinical Research Center, Inc., Orlando, FL, 2Department of Research and Development, Cumberland Pharmaceuticals, Inc., Nashville, TN, USA Purpose: Conivaptan is an intravenous dual V1A/V2 vasopressin antagonist approved for the trea...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2017-02-01
|
| Series: | Drug Design, Development and Therapy |
| Subjects: | |
| Online Access: | https://www.dovepress.com/pharmacokinetics-of-conivaptan-use-in-patients-with-severe-hepatic-imp-peer-reviewed-article-DDDT |